BONESUPPORT, an emerging leader in orthobiologics for the management of bone voids, announces that it has started selling CERAMENT¬Æ BVF direct via its own US distributor network.
Emil Billb√§ck, BONESUPPORT‚Äôs CEO said¬†‚ÄúThe launch of our own US distribution network is a key strategic milestone as we work towards our goal of becoming a global orthobiologics leader focused on the treatment of bone voids. Gaining control of our destiny in the US delivers multiple significant benefits that we are confident will allow us to build a much stronger BONESUPPORT business and deliver significant value to all of our stakeholders.‚Äù
BONESUPPORT created its own network of highly motivated distributors and expanded its US commercial organization to:
- ¬†¬†Access a much larger market opportunity for CERAMENT BVF
- ¬†Increase its ability to drive end-user sales
- ¬†Deliver higher net margins
- ¬†Expand its US product offering
- ¬†Raise brand awareness ahead of the CERAMENT G launch
BONESUPPORT ‚Äòs US network currently consists of 25 high quality distributors, that cover all key areas of the US bone void filler market that the Company is targeting. Together these distributors employ a total of 512 sales reps.
- their close relationships to the leading orthopedic surgeons in their region,
- ¬†a track record of sales success, and
- ¬†dynamic sales reps who spend significant time in the operating theatre with the surgeons who are the key target customers for CERAMENT BVF
BONESUPPORT‚ÄôS own US commercial organization of 21 employees is, in parallel, approaching key national purchasing organizations to ensure that CERAMENT BVF will have access to a growing number of hospitals.
This strengthened US commercial platform will launch new products from its recent agreements with Collagen Matrix Inc. and MTF Biologics, which are complementary to CERAMENT BVF, in the first half of 2019.
Patrick O‚ÄôDonnell, General Manager & Executive Vice President of Commercial Operations North America, said¬†‚ÄúWe are extremely pleased with the strength and reach of the US network of independent distributors that we now have in place. Their highly motivated reps will start selling CERAMENT BVF today targeting orthopedic surgeons, focused on trauma, total joint arthroplasty, foot & ankle, and orthopedic oncology. I am very confident that our new enlarged commercial platform will drive significant US sales growth in 2019 and beyond.‚Äù
BONESUPPORT terminated its exclusive distribution agreement for CERAMENT BVF with Zimmer Biomet (ZB) for the US market in May 2018. Under the terms of this agreement, ZB‚Äôs exclusivity expired on 20 October 2018. ZB will continue to be a non-exclusive distributor of CERAMENT BVF until 21 April 2019.¬†